Tango Therapeutics, Inc.
Here’s whether Tango Therapeutics, Inc. (TNGX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+2.05% over 10 days); RSI 49 — healthy momentum range; strong 1-year return of +476.1%; 3-month momentum positive (+22.9%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 28.8% off its 52-week high. Score: +5/7.
TNGX is holding above its long-term 200-day MA ($13.26) but has slipped below the 50-day MA ($22.47), pointing to short-term weakness in an otherwise intact trend. An RSI of 48.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +476.1% compares to +24.4% for SPY (beat the market by 451.7%). The current 28.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.